On page 7 it says to provide funding to reflect the impact of projected shortfall for costs of blood and plasma protein products. Do you know how many people in that that reflects on the cost here?
Norman Yakeleya on Committee Motion 22-17(4): Concurrence Of Supplementary Estimates (Operations Expenditures), No. 4, 2011-2012, Carried
In the Legislative Assembly on March 12th, 2013. See this statement in context.
Committee Motion 22-17(4): Concurrence Of Supplementary Estimates (Operations Expenditures), No. 4, 2011-2012, Carried
Consideration in Committee of the Whole of Bills and Other Matters
March 11th, 2013
See context to find out what was said next.